Advanced Accelerator Applications (NASDAQ:AAAP) a Novartis company and leader in nuclear medicine theragnostics, today announced that it has received US Food and Drug Administration approval of its new drug application (NDA) for LUTATHERA® (lutetium Lu 177 dotatate) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors. As quoted in the press release: NETs are rare tumors …

Advanced Accelerator Applications (NASDAQ:AAAP) a Novartis company and leader in nuclear medicine theragnostics, today announced that it has received US Food and Drug Administration approval of its new drug application (NDA) for LUTATHERA^®(lutetium Lu 177 dotatate) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
As quoted in the press release:

NETs are rare tumors originating in the neuroendocrine cells of numerous organs, including the gastrointestinal tract, pancreas and lung. Some patients develop symptoms arising from the excessive production of hormones by neuroendocrine tumor cells, while others remain clinically silent for years.

Click here to read the full press release.